A Phase 1b/2 Study of MEDI4736 in Combination with Tremelimumab, MEDI4736 Monotherapy, and Tremelimumab Monotherapy in Subjects with Metastatic or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma
A study patients with metastatic or recurrent Gastric or Gastroesophageal Junction Adencarcinoma using study drug MEDI4736
Sponsor: MedImmune
Enrolling: Male and Female Patients
IRB Number: AAAO8258
U.S. Govt. ID: NCT02340975
Contact: Vulaj Victoria: 646 317 6085 / po2178@columbia.edu
Additional Study Information: This study is being conducted in participants with gastric (stomach) cancer or cancer of the astroesophageal junction (where the esophagus meets the stomach) that has returned after treatment (recurrent), or has spread to another area of your body (metastatic). The main purpose is to determine the doses and dosing schedule of both MEDI4736 and tremelimumab that are safe and tolerable when given together in subjects with gastric (stomach) cancer or cancer of the gastroesophageal junction (where the esophagus meets the stomach). In the second part of this study, adult subjects with metastatic or recurrent gastric cancer or cancer of the gastroesophageal junction will be randomly enrolled into 1 of 4 treatment groups based on previously received treatments for their cancer
This study is closed
Gulam Manji, MD, PhD
Do You Qualify?
Have you had any chemotherapy, immunotherapy, biologic, or hormonal therapy for cancer treatment? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Vulaj Victoria
646 317 6085